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Abstract
Acute HIV-1 infection causes a rapid total body depletion of CD4 + T cells in most individuals and HIV-1-specific
CD8 + T cell expansion in response to viral replication. A numerically high CD8 T cell response may indicate
limited T cell repertoire against HIV and rapid progression. We present a detailed evaluation of an acutely
infected individual with a strong HIV-1-specific CD8 T cell response targeting multiple epitopes demonstrating
that the upper limit of CD8 expansion in this setting may be much higher than previously reported and was
likely driven by the narrow HIV-specific response.
Introduction
Acute HIV-1 infection (AHI) causes a rapid total bodydepletion of CD4 + T cells in most individuals.1,2 Prior
studies have shown that HIV-1-specific CD8 expansion occurs
in the setting of AHI and a substantial proportion of CD8 cells
may be HIV-1 specific.3 The specificity and diversity of the
response likely influence viral set point and disease progres-
sion.4,5 The range of the overall CD8 T cell response (i.e.,
numbers of CD8 + cells) has not been well described.6 A recent
AHI case in North Carolina with markedly elevated total CD8
count prompted us to perform a more detailed analysis of this
individual’s response and examine CD8 cell numbers in our
AHI cohort.
Case Report: In December 2007 a 32-year-old African-
American man with a remote history of Chlamydia urethritis
was admitted to the hospital after presenting with a 2-week
history of fevers to 105F, chills, decreased appetite, weight
loss, sore throat, dysphagia, odynophagia, night sweats,
nausea, and vomiting. On physical examination he was found
to have thrush and bilateral cervical lymphadenopathy
(largest 1.5 cm in diameter). He reported a prior negative HIV
test and a new sexual partner. Three days after admission
HIV-1 enzyme-linked immunosorbent assay (ELISA) was
positive, HIV-1 Western blot was negative, and serum HIV-1
viral load was 5,793,980 copies/ml, consistent with AHI.
Laboratory results included an aspartate aminotransferase
of 666 U/liter (normal 19–55 U/liter), alanine aminotransfer-
ase of 1174 U/liter (normal 19–72 U/liter), and serum lactate
dehydrogenase of 8393 U/liter (normal 338–610 U/liter). An
initial CD4 count was 484 cells/mm3 (7%) with elevated CD8
at 5392 cells/ll (78%) 8 days after admission. He had an un-
detectable serum hepatitis C virus (HCV) and cytomegalovi-
rus (CMV) viral load, and Epstein–Barr virus (EBV) DNA was
detected in the serum at less than 500 copies/ml. EBV serol-
ogies were VCA IgG positive, EBNA positive, and VCA IgM
negative consistent with prior infection. Hepatitis serologies
were negative. The patient remained symptomatic for ap-
proximately 21 days after his admission with fatigue, dys-
phagia, nausea, diarrhea, and abdominal pain.
Eleven days after admission his CD4 count was 300 cells/ll
(2%) and his absolute CD8 count was 13,654 cells/ll (91%).
Seventeen days postadmission the total absolute CD8 count
had risen to 14,459 cells/ll (93%). The very high CD8 levels
were concerning for hematologic malignancy, therefore di-
agnostic PCR-based testing (TCR gene rearrangement) on
peripheral blood was performed to determine cellular clon-
ality of the expanding population. Analysis of gamma chain
rearrangement showed two predominant populations, which
is consistent with a clonal population with both alleles rear-
ranged (biallelic gene rearrangement) or with two separate
clonal populations. This result was consistent with, but not
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diagnostic of, a malignancy such as large granular lympho-
cyte leukemia.7 Antiretroviral medication was started 23 days
after admission and a repeat absolute CD8 count was 7861
cells/mm3 prior to the first dose of therapy. Subsequent CD8
counts on therapy were lower, inconsistent with hematologic
malignancy (Fig. 1). Antiretroviral therapy was offered be-
cause of the severity of the patient’s symptoms, the low CD4
nadir, and the initial concern for malignancy. The risks and
benefits of starting antiretroviral therapy in the setting of
acute infection were discussed with the patient who opted for
starting therapy, anticipating lifelong therapy. We therefore
examined whether the significant CD8 expansion observed in
this patient reflected a very strong adaptive immune response
to acute HIV-1 infection.
Materials and Methods
A portion of the data was obtained as part of the diagnostic
work-up, including the patient’s history, routine laboratory
data, and TCR gamma rearrangement assay to assess for
clonality. The Health Insurance Portability and Account-
ability Act (HIPAA) confidentiality regulations were followed
in compiling this information from the patient’s medical re-
cords and the patient consented for nonidentifying informa-
tion to be included in a clinical report. After informed consent
was obtained, the patient donated blood for laboratory eval-
uation as part of a longitudinal study on acutely infected HIV
patients.
CD8 activation and HIV-specific responses
The frequency of circulating activated CD8 + T cells was
determined by flow cytometric analysis of CD38 and HLA-
DR expression. The magnitude of HIV-1-specific CD8 + T cell
responses was measured using interferon (IFN)-c ELISpot
assays and by multiparameter flow cytometry for the detec-
tion of degranulation (CD107) and production of cytokines
(IFN-c. IL-2, and TNF-a) and the chemokine (MIP-1b) fol-
lowing stimulation with pools of autologous peptides.8 Single
genome amplification was performed to determine the pa-
tient’s transmitted virus sequence.9
Range of absolute CD8 counts among acutely
infected individuals
An analysis of the absolute CD8 + response in multiple
acutely infected HIV-positive individuals was performed
using data collected as part of an acute HIV infection cohort.10
Peak absolute CD8 counts were determined among individ-
uals who had an absolute CD8 count drawn within 6 months
of infection and prior to starting antiretroviral therapy.
Results
CD8 activation and HIV-specific responses
At peak, the absolute number of CD3 + CD8 + cells was
14,459 cells/ll and 91% of total lymphocytes were CD3 +
CD8 + . Among 65 individuals who had been acutely infected
with HIV and had absolute CD8 counts drawn within 6
months of presentation and prior to starting antiretroviral
therapy the mean/median peak CD8 count was 1377/1174
(IQR 761:1486, min 132, max 8776 cells/ml). Only 3 out of 65
peak (5%) CD8 counts were greater than 4000 cells/ml. In this
subset of acutely infected individuals, 43 of the 65 individuals
had a negative enzyme immunoassay (EIA) at the time of
diagnosis when the initial CD8 counts were collected (Fiebig
stage II or earlier).
In this individual the frequency of circulating activated
CD8 + T cells (CD38 + HLA-DR + ) was 92%, substantially
above the normal range observed in healthy individuals
(average 8.9%, range 2.69–22.7%) and well above the median
observed in our cohort of 100 HIV-1 acutely infected subjects
(average 65.6%, range 22.7–95%).
Single genome amplification (SGA) and sequencing tech-
niques demonstrated that this patient was infected with
two closely related viruses. Peptides were synthesized to
match the major transmitted virus. Different cellular assays
were employed to measure the magnitude of HIV-1-specific
CD8 + T cell responses at the peak of CD8 expansion and
before therapy was initiated. Ex vivo IFN-c ELISpot assay re-
vealed strong IFN-c-producing T cell responses to four epi-
topes (Table 1). In subsequent studies, 9% of all CD3 + /CD8 +
T cells were responding to a single epitope, binding the
FIG. 1. CD8 counts on therapy.
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YPLTFGWCY B*0702 tetramer. Multiparameter flow cytom-
etry to detect degranulation and production of IFN-c, IL-2,
TNF-a, and MIP-1b following 6 h stimulation with autologous
(matching founder virus) and consensus clade B peptide pools
revealed that the frequency of HIV-1 Env-, Gag-, and Nef-
specific CD8 + T cells represented 18% of the total memory
CD8 + T cell subset. The standard method of overnight rest
followed by 6 h of antigen-specific stimulation of the T cell
population resulted in a loss of 50% of the cells when com-
pared to cell recoveries in chronically infected individuals.
The rapid loss of CD8 viability suggests the measured fraction
of HIV-1-specific cells underestimates the total HIV-specific
response given that only viable cells can be quantified. In
addition, HIV-1-specific T cells could not be expanded in vitro,
further supporting the HLA-DR/CD38 phenotyping data
that cells were highly activated and most likely terminally
differentiated.
Discussion
This case demonstrates a massive CD8 expansion in the
setting of acute HIV infection that was associated with a se-
vere symptomatic infection and a rapid decline in peripheral
CD4 count. In the absence of any evidence of malignancy, the
strong CD8 cell expansion observed likely reflects the rapid
expansion of HIV-1-specific CD8 T cells following infection.
We cannot exclude activation and cytokine-driven expansion
of non-HIV-1-specific T cells or significant immune system
dysfunction, but if non-HIV-1-specific expansion of T cells did
occur, it was not reflected in the CMV T cell response to the
pp65 TPRVTGGGAM epitope, which was detectable but 50-
to 79-fold lower in magnitude than the mapped HIV-1-
specific responses (Table 1). In addition, assuming a relation-
ship between specific IFN-c secretion as measured by ELISpot
and tetramer frequency,11 as many as 20% of CD8 T cells in
this patient were directed at the four epitopes identified. High
frequencies of HIV-1-specific T cells have been reported in
other studies, with studies by Wilson et al.3 reporting HIV-1
tetramer-specific frequencies approaching 4% in acute in-
fection and Papagno et al.12 reporting frequencies of 10%
tetramer-positive CD8 T cells in chronic HIV-1 infection. More
recently, Ferrari et al.,13 employing intracellular cytokine and
degranulation (IFN-c, IL-2, TNF-a, MIP-b, CD107) flow cy-
tometry techniques, reported frequencies of acute HIV-1epi-
tope-specific CD8 T cells in the range of from 0.65 to 7.29% of
the total CD8 population within the first 4 weeks of infection.
The capacity of the T cell response to expand rapidly in acute
viral infections is best demonstrated by studies of acute EBV
infection where EBV-specific CD8 T cells comprised up to 44%
of the total CD8 T cell response.14
The 40% contraction of absolute CD8 cells within 5 days
and results from in vitro assays suggested that cells were
functional but highly apoptopic and poorly replicative. These
observations are consistent with primary T cell responses and
kinetics to live attenuated yellow fever vaccines15 and mouse
models of virus infection16 that describe strong activation and
expansion of virus-specific primarily effector T cells within
weeks of infection followed by a contraction phase limiting
the duration of the primary T cell response preventing im-
munopathology that would no doubt result if T cell expansion
remained unchecked.
Recent studies have shown that primary T cell responses
make a significant contribution to killing of virus-infected
cells but may also select for rapid viral escape during acute
viremia.8 Because this patient went on antiretroviral therapy
within weeks of admission we have insufficient data on
whether these primary HIV-1-specific T cell responses se-
lected for viral escape. It is notable, however, that there was a
1.5 log drop in viremia over a 10-day period coincident to the
detection of HIV-1-specific T cell responses. Previous studies
on CD8 expansion during AHI have demonstrated that HIV-
1-specific expansion may represent a limited T cell repertoire,
and may be associated with more rapid progression. Con-
versely, Ferrari et al.13 described the CD8 + T cell response to
acute HIV infection in symptomatic patients. They did not see
an association with the magnitude of CD8 + T cell response
and the appearance of escape mutants. In this individual, the
height of the CD8 T cell response, the systemic symptoms, and
elevated LFT in the setting of clonality by TCR gene re-
arrangement raised concerns that the patient may have pre-
sented with a malignant or premalignant syndrome. The
rapid decline in CD8 count and the subsequent epitope
analysis were not consistent with malignancy.
The question of whether this CD8 cell response was targeted
entirely or predominantly against HIV is difficult to answer,
but the HIV-specific response was robust, the proportion of
activated CD8 cells was remarkably high,and despite the level
of immune activation levels of other common viral pathogens
(CMV and EBV) were either not detected or below quantifi-
cation. Certainly the magnitude of the CD8 T cell response
contributed to the patient’s clinical illness, but whether the re-
sponse was ineffectual is not certain. We note that the CD4 cell
count was rising and the CD8 count and plasma HIV RNA
were falling prior to the institution of antiretroviral therapy,
which his clinicians believed was indicated based on the
symptoms, CD4 decline, and CD8 expansion data at the time.





(% of CD3/CD8 T cells) Restriction
HIV-1 GP160(585–593)a RYLKDQQLL 4220 ND CW*0702
HIV Integrase (263–271) RKAKIIRDY 2255 ND B*1503
HIV NEF (135–143) YPLTFGWCY 9180 9.0% B*0702
HIV ENV (637–645) NYTSLIYNL 4615 ND CW*0702
HCMV pp65 (415–429)b TPRVTGGGAM 160 ND B*07
aAmino acid alignment relative to HXB2 strain.
bAlignment relative to HCMV AD169 strain.
IFN-c, interferon gamma; PBMC, peripheral blood mononuclear cells.
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In conclusion, this case demonstrates that the magnitude of
immune activation accompanying AHI can extend beyond
what has been described to the point of mimicking malig-
nancy. This massive expansion of CD8 T cells could have
contributed to the severe symptoms seen in this individual
and may reflect a profound disregulation of the T cell com-
partment. These results provide insights into the diversity of
response to acute HIV infection.
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